Patent Term Extension Application for KYGEVVI (doxecitine and doxribtimine), Patent No. 10,471,087 | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

FDA-2026-E-1009

Patent Term Extension Application for KYGEVVI (doxecitine and doxribtimine), Patent No. 10,471,087

Documents

Comments

Description

OPEN

Comment Period OpensFeb 2, 2026

Type	Title	Posted	Comments	Status
Other	Letter to U. S. Patent and Trademark Office	Apr 20, 2026	--

CDER

Patent Term Extension Application

Covington & Burling LLP

The Trustees of Columbia

University in the City of New York

KYGEVVI (doxecitine and doxribtimine)

Patent No. 10,471,087

OPEN